Vir Biotechnology, Inc. (VIR) Q3 2025 10-Q Quarterly Report
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Vir Biotechnology, Inc. (VIR) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Vir Biotechnology, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: FDA revoked EUA for sotrovimab COVID-19 treatment December 2024, eliminating expected future US revenue from this product
- • Material update: Net loss $395.1M for nine months ended Sept 30, 2025 vs prior $417.4M period; accumulated deficit $1.2B reflects ongoing R&D investment
- • Regulatory risk: Potential for FDA and foreign authorities to impose costly additional studies or restrictive labeling even post-approval for product candidates
- • Operational risk: Reliance on third parties for clinical supplies and trials creates vulnerability to delays impacting near-term development timelines
- • Financial risk: Cash, equivalents, and investments of $810.7M as of Sept 30, 2025 expected to fund at least 12 months, but future capital raising uncertain due to economic and geopolitical instability
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.